Granules India Limited has informed the Exchange about General Updates
GRANULES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Granules India informed the exchanges that the US FDA carried out a Pre-Approval Inspection (PAI) at its wholly-owned US subsidiary Granules Pharmaceuticals Inc.'s facility in Chantilly, Virginia from June 23 to June 27, 2025. The inspection was for a first-to-file controlled substance ANDA (Abbreviated New Drug Application). The inspection closed with one Form 483 observation, which the company says it addressed and resolved during the inspection itself, with no further escalation to a Warning Letter or Import Alert mentioned.
This is a mildly positive development as the only 483 observation was resolved on the spot, keeping the path open for potential approval of the first-to-file controlled substance ANDA, which could offer meaningful US market exclusivity if approved. No negative regulatory action was reported, and there is no immediate impact on existing revenue or guidance.